Zai Lab Statement on Executive Management Team's Agreement on Share Activities
The Executive Officers of Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), Samantha Du, Josh Smiley, Rafael Amado, Harald Reinhart, Yajing Chen, F. Ty Edmondson, as well as Jonathan Wang, today announced that they have each agreed that they do not anticipate selling any shares in Zai Lab through the remainder of 2024, except for any shares in existing Rule 10b5-1 plans that are currently effective or to cover tax obligations associated with the vesting of equity awards.
About Zai Lab
Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, autoimmune disorders, infectious disease, and neuroscience. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide.
For additional information about Zai Lab, including our products, business activities and partnerships, research, and other events or developments, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.
Digital health ecosystem for more than 60 insurers, Santéclair, extends partnership with Ada Health, increasing the number of care options Ada's AI can direct members to.Partnership guides members to appropriate services across a network of over...
The acclaimed educational program Empowered, hosted by Meg Ryan, is proud to announce an upcoming episode that will shed light on the toll of addiction and explore the vital work being done by the Houston Recovery Center to guide individuals toward...
September is Falls Prevention Awareness Month. The goal is simple: keep older people on their feet. But achieving it isn't easy. It requires changes in behavior, environment, and sometimes even medications. The first step is understanding risk...
Research by Genomics plc has identified that 8% of the adult population have the same risk of heart disease due to polygenic risk, as carriers of rare genetic mutations that cause Familial hypercholesterolemia (FH).NHS testing currently focuses on...
Experts at Compliancy Group predict HHS OCR likely to focus HIPAA Phase 3 Audits on risk analysis and risk management.
In 2023, OCR launched a new enforcement initiative...